Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
FASEB J ; 33(11): 12500-12514, 2019 11.
Article in English | MEDLINE | ID: mdl-31408613

ABSTRACT

The tetraspanin CD82 is a potent suppressor of tumor metastasis and regulates several processes including signal transduction, cell adhesion, motility, and aggregation. However, the mechanisms by which CD82 participates in innate immunity are unknown. We report that CD82 is a key regulator of TLR9 trafficking and signaling. TLR9 recognizes unmethylated cytosine-phosphate-guanine (CpG) motifs present in viral, bacterial, and fungal DNA. We demonstrate that TLR9 and CD82 associate in macrophages, which occurs in the endoplasmic reticulum (ER) and post-ER. Moreover, CD82 is essential for TLR9-dependent myddosome formation in response to CpG stimulation. Finally, CD82 modulates TLR9-dependent NF-κB nuclear translocation, which is critical for inflammatory cytokine production. To our knowledge, this is the first time a tetraspanin has been implicated as a key regulator of TLR signaling. Collectively, our study demonstrates that CD82 is a specific regulator of TLR9 signaling, which may be critical in cancer immunotherapy approaches and coordinating the innate immune response to pathogens.-Khan, N. S., Lukason, D. P., Feliu, M., Ward, R. A., Lord, A. K., Reedy, J. L., Ramirez-Ortiz, Z. G., Tam, J. M., Kasperkovitz, P. V., Negoro, P. E., Vyas, T. D., Xu, S., Brinkmann, M. M., Acharaya, M., Artavanis-Tsakonas, K., Frickel, E.-M., Becker, C. E., Dagher, Z., Kim, Y.-M., Latz, E., Ploegh, H. L., Mansour, M. K., Miranti, C. K., Levitz, S. M., Vyas, J. M. CD82 controls CpG-dependent TLR9 signaling.


Subject(s)
Cell Nucleus/immunology , Kangai-1 Protein/immunology , Macrophages/immunology , Oligodeoxyribonucleotides/pharmacology , Signal Transduction/drug effects , Toll-Like Receptor 9/immunology , Active Transport, Cell Nucleus/drug effects , Active Transport, Cell Nucleus/genetics , Active Transport, Cell Nucleus/immunology , Animals , Cell Nucleus/genetics , Cytokines/genetics , Cytokines/immunology , Endoplasmic Reticulum/genetics , Endoplasmic Reticulum/immunology , Endoplasmic Reticulum/pathology , Inflammation/genetics , Inflammation/immunology , Inflammation/pathology , Kangai-1 Protein/genetics , Macrophages/pathology , Mice , Mice, Knockout , NF-kappa B/genetics , NF-kappa B/immunology , RAW 264.7 Cells , Signal Transduction/genetics , Signal Transduction/immunology , Toll-Like Receptor 9/genetics
2.
J Immunol ; 202(11): 3256-3266, 2019 06 01.
Article in English | MEDLINE | ID: mdl-31010852

ABSTRACT

Tetraspanins are a family of proteins possessing four transmembrane domains that help in lateral organization of plasma membrane proteins. These proteins interact with each other as well as other receptors and signaling proteins, resulting in functional complexes called "tetraspanin microdomains." Tetraspanins, including CD82, play an essential role in the pathogenesis of fungal infections. Dectin-1, a receptor for the fungal cell wall carbohydrate ß-1,3-glucan, is vital to host defense against fungal infections. The current study identifies a novel association between tetraspanin CD82 and Dectin-1 on the plasma membrane of Candida albicans-containing phagosomes independent of phagocytic ability. Deletion of CD82 in mice resulted in diminished fungicidal activity, increased C. albicans viability within macrophages, and decreased cytokine production (TNF-α, IL-1ß) at both mRNA and protein level in macrophages. Additionally, CD82 organized Dectin-1 clustering in the phagocytic cup. Deletion of CD82 modulates Dectin-1 signaling, resulting in a reduction of Src and Syk phosphorylation and reactive oxygen species production. CD82 knockout mice were more susceptible to C. albicans as compared with wild-type mice. Furthermore, patient C. albicans-induced cytokine production was influenced by two human CD82 single nucleotide polymorphisms, whereas an additional CD82 single nucleotide polymorphism increased the risk for candidemia independent of cytokine production. Together, these data demonstrate that CD82 organizes the proper assembly of Dectin-1 signaling machinery in response to C. albicans.


Subject(s)
Candida albicans/physiology , Candidiasis/metabolism , Cell Membrane/metabolism , Kangai-1 Protein/metabolism , Lectins, C-Type/metabolism , Macrophages/immunology , Phagosomes/metabolism , Animals , Candidiasis/immunology , Cell Line , Genetic Predisposition to Disease , Humans , Immunity, Cellular , Interleukin-1beta/metabolism , Kangai-1 Protein/genetics , Lectins, C-Type/genetics , Membrane Microdomains/metabolism , Mice , Mice, Inbred C57BL , Mice, Knockout , Polymorphism, Single Nucleotide , Signal Transduction , Tumor Necrosis Factor-alpha/metabolism
3.
Virulence ; 9(1): 1150-1162, 2018.
Article in English | MEDLINE | ID: mdl-29962263

ABSTRACT

Candida spp. are the fourth leading cause of nosocomial blood stream infections in North America. Candida glabrata is the second most frequently isolated species, and rapid development of antifungal resistance has made treatment a challenge. In this study, we investigate the therapeutic potential of metformin, a biguanide with well-established action for diabetes, as an antifungal agent against C. glabrata. Both wild type and antifungal-resistant isolates of C. glabrata were subjected to biguanide and biguanide-antifungal combination treatment. Metformin, as well as other members of the biguanide family, were found to have antifungal activity against C. glabrata, with MIC50 of 9.34 ± 0.16 mg/mL, 2.09 ± 0.04 mg/mL and 1.87 ± 0.05 mg/mL for metformin, phenformin and buformin, respectively. We demonstrate that biguanides enhance the activity of several antifungal drugs, including voriconazole, fluconazole, and amphotericin, but not micafungin. The biguanide-antifungal combinations allowed for additional antifungal effects, with fraction inhibition concentration indexes ranging from 0.5 to 1. Furthermore, metformin was able to lower antifungal MIC50 in voriconazole and fluconazole-resistant clinical isolates of C. glabrata. We also observed growth reduction of C. glabrata with rapamycin and an FIC of 0.84 ± 0.09 when combined with metformin, suggesting biguanide action in C. glabrata may be related to inhibition of the mTOR complex. We conclude that the biguanide class has direct antifungal therapeutic potential and enhances the activity of select antifungals in the treatment of resistant C. glabrata isolates. These data support the further investigation of biguanides in the combination treatment of serious fungal infections.


Subject(s)
Antifungal Agents/pharmacology , Biguanides/pharmacology , Candida glabrata/drug effects , Candida/drug effects , Amphotericin B/pharmacology , Candida glabrata/growth & development , Drug Combinations , Drug Resistance, Fungal , Echinocandins/pharmacology , Fluconazole/pharmacology , Humans , Lipopeptides/pharmacology , Metformin/pharmacology , Micafungin , Microbial Sensitivity Tests , Mycoses/drug therapy , Mycoses/microbiology , TOR Serine-Threonine Kinases/drug effects , Voriconazole/pharmacology
SELECTION OF CITATIONS
SEARCH DETAIL
...